Publikasi Scopus 2024 per tanggal 30 Juni 2024 (499 artikel)

Publikasi Scopus 2024 per tanggal 30 Juni 2024 (499 artikel)

Corduff N.; Park J.-Y.; Calderon P.E.; Choi H.; Dingley M.; Ho W.W.S.; Martin M.U.; Suseno L.S.; Tseng F.-W.; Vachiramon V.; Wanitphakdeedecha R.; Yu J.N.T.
Corduff, Niamh (7801565751); Park, Je-Young (57113852900); Calderon, Pacifico E. (57777897000); Choi, Hosung (57766086300); Dingley, Mary (57778575200); Ho, Wilson W.S. (56909376500); Martin, Michael U. (57777897100); Suseno, Lis S. (57202804092); Tseng, Fang-Wen (59183482500); Vachiramon, Vasanop (24330191600); Wanitphakdeedecha, Rungsima (14040758200); Yu, Jonathan N.T. (57129203200)
7801565751; 57113852900; 57777897000; 57766086300; 57778575200; 56909376500; 57777897100; 57202804092; 59183482500; 24330191600; 14040758200; 57129203200
Real-world Implications of Botulinum Neurotoxin A Immunoresistance for Consumers and Aesthetic Practitioners: Insights from ASCEND Multidisciplinary Panel
2024
Plastic and Reconstructive Surgery - Global Open
12
6
e5892
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196648000&doi=10.1097%2fGOX.0000000000005892&partnerID=40&md5=2df70e082bbbfdbd93a620a1832ae198
Geelong, VIC, Australia; Apkoo-Jung Oracle Dermatology Clinic, Seoul, South Korea; Department of Professionalism, Medical Ethics and Humanities, College of Medicine, and Clinical Ethics Services, St. Luke’s Medical Center, Quezon City, Philippines; Piena Clinic, Seoul, South Korea; The Cosmetic Medicine Centre, Toowong, QLD, Australia; The Specialists:, Lasers, Aesthetics and Plastic Surgery, Central, Hong Kong; Lower Saxony, Springe, Germany; Division of Cosmetic Dermatology, Department of Dermatology and Venereology, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Taoyuan Milano Aesthetic Clinic, Taoyuan City, Taiwan; Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; JY Dermatology and Aesthetic Center, Metro Manila, Philippines
Corduff N., Geelong, VIC, Australia; Park J.-Y., Apkoo-Jung Oracle Dermatology Clinic, Seoul, South Korea; Calderon P.E., Department of Professionalism, Medical Ethics and Humanities, College of Medicine, and Clinical Ethics Services, St. Luke’s Medical Center, Quezon City, Philippines; Choi H., Piena Clinic, Seoul, South Korea; Dingley M., The Cosmetic Medicine Centre, Toowong, QLD, Australia; Ho W.W.S., The Specialists:, Lasers, Aesthetics and Plastic Surgery, Central, Hong Kong; Martin M.U., Lower Saxony, Springe, Germany; Suseno L.S., Division of Cosmetic Dermatology, Department of Dermatology and Venereology, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Tseng F.-W., Taoyuan Milano Aesthetic Clinic, Taoyuan City, Taiwan; Vachiramon V., Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Wanitphakdeedecha R., Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Yu J.N.T., JY Dermatology and Aesthetic Center, Metro Manila, Philippines
Background: As long-term, regular aesthetic botulinum neurotoxin A (BoNT-A) use becomes more commonplace, it is vital to understand real-world risk factors and impact of BoNT-A immunoresistance. The first Aesthetic Council on Ethical Use of Neurotoxin Delivery panel discussed issues relating to BoNT-A immunoresistance from the health care professionals’ (HCPs’) perspective. Understanding the implications of BoNT-A immunoresistance from the aesthetic patient’s viewpoint allows HCPs to better support patients throughout their aesthetic treatment journey. Methods: A real-world consumer study surveyed 363 experienced aesthetic BoNT-A recipients across six Asia-Pacific territories. The survey mapped participants’ BoNT-A aesthetic treatment journey and characterized awareness and attitudes relating to BoNT-A immunoresistance and treatment implications. At the second Aesthetic Council on Ethical use of Neurotoxin Delivery meeting, panelists discussed survey findings and developed consensus statements relating to the impact of BoNT-A immunoresistance on the aesthetic treatment journey. Results: Aesthetic BoNT-A patients’ depth of knowledge about BoNT-A immunoresistance remains low, and risk/benefit communications need to be more lay-friendly. The initial consultation is the most important touchpoint for HCPs to raise awareness of BoNT-A immunoresistance as a potential side effect considering increased risk with repeated high-dose treatments. HCPs should be cognizant of differences across BoNT-A formulations due to the presence of certain excipients and pharmacologically unnecessary components that can increase immunogenicity. Standardized screening for clinical signs of secondary nonresponse and a framework for diagnosing and managing immunoresistance-related secondary nonresponse were proposed. Conclusion: These insights can help patients and HCPs make informed treatment decisions to achieve desired aesthetic outcomes while preserving future treatment options with BoNT-A. Copyright © 2024 The Authors.
Merz Aesthetics; Merz Aesthetics, Galderma, and Allergan
Funding text 1: The authors dedicate this work to the memory of Dr. Wilson W. S. Ho, who unexpectedly passed away in January 2024. In addition to being an esteemed colleague and friend, Dr. Ho made important contributions to the field of plastic surgery and aesthetic medicine and was an integral part of this author group\u2019s efforts to contribute to the discourse on evolving and future use of B
Lippincott Williams and Wilkins
21697574
Article
Q2
671
7496

Unit Riset FKUI/Medical Research Unit
Gedung IMERI Tower Riset lt. 9, Jl. Salemba Raya No. 6, Jakarta Pusat, 10430
Telp. : +62 21 29189160 (ext. 201912)
E-mail : manajer.riset.fkui1@gmail.com